Perspectives in melanoma: meeting report from the “Melanoma Bridge” (December 5th–7th, 2019, Naples, Italy)

The melanoma treatment landscape changed in 2011 with the approval of the first anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 checkpoint inhibitor and of the first BRAF-targeted monoclonal antibody, both of which significantly improved overall survival (OS). Since then, improved understand...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:J Transl Med
المؤلفون الرئيسيون: Ascierto, Paolo A., Puzanov, Igor, Agarwala, Sanjiv S., Blank, Christian, Carvajal, Richard D., Demaria, Sandra, Dummer, Reinhard, Ernstoff, Marc, Ferrone, Soldano, Fox, Bernard A., Gajewski, Thomas F., Garbe, Claus, Hwu, Patrick, Lo, Roger S., Long, Georgina V., Luke, Jason J., Osman, Iman, Postow, Michael A., Sullivan, Ryan J., Taube, Janis M., Trinchieri, Giorgio, Zarour, Hassane M., Caracò, Corrado, Thurin, Magdalena
التنسيق: Artigo
اللغة:Inglês
منشور في: BioMed Central 2020
الموضوعات:
Meeting Report
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC7487701/
https://ncbi.nlm.nih.gov/pubmed/32894202
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-020-02482-x
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة